Cite

HARVARD Citation

    Holz, F. et al. (2022). A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 42 (9), pp. 1629-1637. [Online]. 
  
Back to record